öλÔÓéÀֵǼÈë¿ÚÏÂÔØ

µ¼Ê¦ÐÕÃû£º½ªÌÎ
ÐÔ±ð£º
ÈËÆøÖ¸Êý£º34

ËùÊôԺУ£º´óÁ¬Ò½¿Æ´óѧ
ËùÊôԺϵ£ºµÚÒ»ÁÙ´²Ñ§Ôº
Ö°³Æ£º½ÌÊÚ
µ¼Ê¦ÀàÐÍ£º²©µ¼
ÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£º


¸öÈ˼òÊö :
½ªÌΣ¬Ò½Ñ§²©Ê¿£¬½ÌÊÚ£¬²©Ê¿Éúµ¼Ê¦£¬ÁÉÄþÊ¡µÚËÄÅú°ÙǧÍòÈ˲Ź¤³ÌǧÈ˲ã´Î£¬ÃÀ¹úÃÚÄòÍâ¿Æѧ»á»áÔ±(ID:**), ¹ú¼ÊÐÔҽѧ»á»áÔ±£¬´óÁ¬ÊÐÎ÷¸ÚÇøÕþЭίԱ£¬µÚ2½ìÖйúÊ®´óÄпƿÆÆÕר¼Ò£¬´óÁ¬Ò½¿Æ´óѧ¸½ÊôÒ»ÔºµÚÒ»½ìÃûÒ½ÈëÑ¡Õß¡£1987Ä꿼ÈëÖйúÒ½¿Æ´óѧ±¾¿Æ£¬1994Ä꿼ȡ´óÁ¬Ò½Ñ§ÔºË¶Ê¿Ñо¿Éú£¬1997Äê±ÏÒµÁôУÈÎÃÚÄòÍâ¿ÆÖ÷ÖÎҽʦ£¬2001Äê¹¥¶Á´óÁ¬Ò½¿Æ´óѧÖÐÎ÷Ò½½áºÏÔÚÖ°²©Ê¿Ñо¿Éú£¬2002Äê½úÉýΪ¸±Ö÷ÈÎҽʦ£¬2004Äê»ñµÃ²©Ê¿Ñ§Î»£¬2007Äê½úÉýÖ÷ÈÎҽʦ£¬2007ÄêƸΪ´óÁ¬Ò½¿Æ´óѧ˶ʿÑо¿Éúµ¼Ê¦£¬2008ÄêתÆÀΪ½ÌÊÚ£¬2011Äêµ£ÈÎÃÚÄòÍâ¿Æ¸±Ö÷ÈΣ¬2016Äêµ£ÈÎÃÚÄòÄпÆÖ÷ÈΣ¬2016ÄêƸΪ´óÁ¬Ò½¿Æ´óѧ²©Ê¿Ñо¿Éúµ¼Ê¦£¬ÏȺóÔÚ±±¾©´óѧµÚÈýÒ½Ôº£¬±±´óÒ½ÔººÍÃÀ¹ú¿µÄζû´óѧ£¬ÃÀ¹úµÂÖÝ´óѧMD AndersonÒ½ÔººÍHermanÒ½ÔºÑÐÐÞѧϰ¡£

¿ÆÑй¤×÷ :
¿ÆÑÐÇé¿ö£º
1£©Ñо¿¿ÎÌ⣺Ö÷³Ö°üÀ¨¹ú¼Ò×ÔÈ»¿Æѧ»ù½ðÔÚÄڵĹú¼Ò¼°Ê¡¼¶¿ÎÌâ4Ï»ñµÃ×ÊÖú¾­·Ñ½ü200ÍòÔª£¬ÈçÏ£º
Äê ¶È »ù½ðÖÖÀà »ù½ðÏîÄ¿Ãû³ÆºÍ±àºÅ ½ð¶î£¨ÍòÔª£© ÏÖ¿ö2006-2008 ÁÉÄþÊ¡²©Ê¿¿ÆÑÐÆô¶¯»ù½ð Ç°ÁÐÏÙ°©Ô¤ºó·Ö×Ó±ê¼Ç̽ÌÖ¼°Ó¦ÓÃÈýÑõ»¯¶þÉéÖÎÁƵÄÑо¿£¨**£© 3 Íê³É
2006-2008 ÁÉÄþÊ¡½ÌÓýÌü¿Æѧ¼¼ÊõÑо¿ÏîÄ¿ ÈýÑõ»¯¶þÉéÓÕµ¼ÐÛ¼¤ËØ·ÇÒÀÀµÇ°ÁÐÏÙ°©Ï¸°ûµòÍö¼°Ç°ÁÐÏÙ°©Ô¤ºó±ê¼ÇÎïÑо¿£¨05L095£© 1.5 Íê³É
2013-2016 ¹ú¼Ò×ÔÈ»¿Æѧ»ù½ðÃæÉÏÏîÄ¿ ÈýÑõ»¯¶þÉéÓÕµ¼ÐÛ¼¤ËØ·ÇÒÀÀµÇ°ÁÐÏÙ°©µòÍöMAPKͨ·¼°VK3ЭͬӦÓõÄÑо¿£¨**£© 80 ÔÚÑÐ
2016-2019 ÁÉÄþÊ¡×ÔÈ»¿Æѧ»ù½ðÃæÉÏÏîÄ¿ SFRP-1ÔÚÈýÑõ»¯¶þÉéÓÕµ¼Ç°ÁÐÏÙ°©Ï¸°ûµòÍöµÄ×÷ÓÃÑо¿£¨**£© 5 ÔÚÑÐ
2£©·¢±íÂÛÎÄ£ºÒÔµÚÒ»×÷Õß»òͨѶ×÷Õß¹²·¢±íÂÛÎÄ30ƪ£¬ÆäÖб»SCIÊÕ¼ÔÓÖ¾µÄÓÐ5ƪ£¬½ü3ÄêÒÔµÚÒ»×÷Õß»òͨѶ×÷Õß·¢±íÂÛÎÄÈçÏ£º
1£©Tao Jiang , Lei Zheng ,Xiao-Ming Su , Jin-Qiang Peng , Dong-Chen Sun , Quan-Lin Li ,Zhi-Wei Zhang , Fa-Peng Wang and Hui Jiang . Long-term testosterone supplementation is useful for ED with testosterone deficiency Asian Journal of Andrology. 2013,15(5),699-700 £¨IF£º2.596£©
2£© Tao Jiang , Lei Zheng ,Xiao-Ming Su , Jin-Qiang Peng , Dong-Chen Sun , Quan-Lin Li ,Zhi-Wei Zhang , Fa-Peng Wang and Hui Jiang . Treatment of pituitary prolactinoma reverses unresponsiveness to PDE5 inhibitor therapy in men with ED and SHPPL Asian Journal of Andrology 2013,15(6),847-849 £¨IF£º2.596£©
3) Zheng L, Sun D, Fan W, Zhang Z, Li Q, Jiang T. Diagnostic Value of SFRP1 as a Favorable Predictive and Prognostic Biomarker in Patients with Prostate Cancer[J].PLoS One, 2015,10(2):e**. £¨IF£º3.5£©
4£©Zhang Z, Jiang T, Li Q, Wang J, Yang D, Li X, Wang Q, Song X £¬Nodal activates smad and extracellular signal-regulated kinases 1/2 pathways promoting renal cell carcinoma proliferation. Mol Med Rep. 2015 Jul 12(1):587-94. £¨ IF:1.554£©5£©Zheng L, Jiang H, Zhang ZW ,Wang KN, Wang QF, Li QL, Jiang T. Arsenic trioxide inhibits viability and induces apoptosis through reactivating the Wnt inhibitor secreted frizzled related protein-1 in prostate cancer cells OncoTargets and Therapy 2016,9:885-894£¨ IF:2.311£©
6£©½ªÌÎ,Ö£ÀÚ,ËÕÏþÃ÷,Åí½øÇ¿,Ëﶬ³¿,ÀîȪÁÖ,ÕÅ־ΰ,Íõ·¨Åô,½ª»Ô. ÒÔÖضÈEDΪÊ×·¢Ö¢×´µÄ´¹ÌåÃÚÈéËØÁö4Àý±¨¸æ, ¡¶ÖлªÄпÆѧÔÓÖ¾¡·£¬2014,20(2)£º141-143
7£© ½ªÌÎ,Ö£ÀÚ, Ëﶬ³¿,ÀîȪÁÖ,ÕÅ־ΰ,Íõ·¨Åô,ÍõÆô·É,½ª»Ô.غͪÌæ´úÖÎÁÆÐÛ¼¤ËØȱ·¦ED»¼Õß65¸öÔÂ1Àý±¨¸æ¼°ÎÄÏ׸´Ï°, ¡¶ÖлªÄпÆѧÔÓÖ¾¡·£¬2013,19(2)£º152-155
8£©½ªÌÎ,Ö£ÀÚ,ËÕÏþÃ÷,Åí½øÇ¿,Ëﶬ³¿,ÀîȪÁÖ,ÕÅ־ΰ,Íõ·¨Åô,½ª»Ô.°òë×¹ÂÁ¢ÐÔÏËάÁöÖ³öѪÐÔÐÝ¿ËÒ»Àý[J]. ÖлªÍâ¿ÆÔÓÖ¾ 2013,51(5)£º4609£© ËÕÏþÃ÷£¨Ñо¿Éú£©,½ªÌΣ¬Ö£ÀÚ, Åí½øÇ¿, Ëﶬ³¿,ÀîȪÁÖ,ÕÅ־ΰ. ÈýÑõ»¯¶þÉéÓÕµ¼Ç°ÁÐÏÙ°©PC-3ϸ°ûµòÍöP38ÐźÅͨ·µÄÑо¿. ¡¶ÖлªÄпÆѧÔÓÖ¾¡·2013,19(7)£º583¡ª587
10£© Åí½øÇ¿£¨Ñо¿Éú£©,½ªÌÎ,Ö£ÀÚ,Ëﶬ³¿,ËÕÏþÃ÷,ÕÅ־ΰ,ÀîȪÁÖ. TT¡¢TSI¡¢FTIÆÀ¹ÀÄÐÐÔÐÛ¼¤ËØˮƽ¼ÛÖµµÄ³õ²½Ñо¿. ¡¶ÖйúÐÔ¿ÆѧÔÓÖ¾¡·2013,22(10)£º45¡ª49
11£©Åí½øÇ¿£¨Ñо¿Éú£©£¬½ªÌΣ¬ÅèÇ»¹ÂÁ¢ÐÔÏËάÁö1Àý±¨¸æ[J]. ÖлªÃÚÄòÍâ¿ÆÔÓÖ¾201334(8):638
3£©Öø×÷£º1£©¸±Ö÷±à£º¡¶ÅÅÓǽâÄÐÌâ¡· 2014Äê ±±¾©´óѧҽѧ³ö°æÉ磨ISBN 978-7-5659-0965-8£©
½±Àø¼°³É¹ûÇé¿öÏȺó»ñÁÉÄþÊ¡Õþ¸®¿Æ¼¼½ø²½2µÈ½±1Ï3µÈ½±4Ï´óÁ¬ÊпƼ¼½ø²½1µÈ½±1Ï´óÁ¬ÊÐ×ÔÈ»¿ÆѧÂÛÎÄ2µÈ½±1Ï´óÁ¬Ò½¿Æ´óѧ¸½ÊôµÚһҽԺм¼Êõ2µÈ½±1Ï3µÈ½±2Ïî¡£
Äê¶È ½±ÀøÖÖÀà »ñ½±ÏîÄ¿Ãû³Æ¼°Ö¤Êé±àºÅ µÈ¼¶ ÅÅÃû
1998 ÁÉÄþÊ¡Õþ¸®¿Æ¼¼½ø²½½± îؼ¤¹âÖÎÁÆÃÚÄòÍâ¿Æ¼²²¡ÊµÑéÓëÁÙ´²Ñо¿£¨98Ò½-3-23-02£© 3 2
2001 ÁÉÄþÊ¡Õþ¸®¿Æ¼¼½ø²½½± PA¾úëÖê¾úÃç°òë×¹à×¢Ô¤·À°òë×°©Êõºó¸´·¢ÊµÑéÓëÁÙ´²Ñо¿ £¨2001J-3-126-02£© 3 2
2003 ÁÉÄþÊ¡Õþ¸®¿Æ¼¼½ø²½½± °òë×°©·¢Éú·¢Õ¹Óë×ÛºÏÖÎÁƼ°Ô¤ºó¼à²âµÄϵÁÐÑо¿ £¨2003J-2-58-03£© 2 3
2006 ÁÉÄþÊ¡Õþ¸®¿Æ¼¼½ø²½½± ±£ÁôÉöµ¥Î»ÊÖÊõÖÎÁÆÉö°©µÄÁÙ´²Ó¦ÓÃÑо¿£¨2006J-3-151-05£© 3 5
2009 ´óÁ¬ÊÐÕþ¸®¿Æ¼¼½ø²½½± ÔçÆÚÉöϸ°û°©Ð¡ÇÐÔµ±£ÉöÊÖÊõµÄ»ù´¡ÓëÁÙ´²Ñо¿£¨2009J-1-16-03£© 1 3
2011 ÁÉÄþÊ¡Õþ¸®¿Æ¼¼½ø²½½± ÔçÆÚÉöϸ°û°©Ð¡ÇÐÔµ±£ÉöÊÖÊõµÄ»ù´¡ÓëÁÙ´²Ñо¿ £¨2011J-3-106-03 £© 3 3